Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2016 1
2017 1
2018 2
2019 1
2020 1
2021 1
2022 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean michael f byrne[Author] (82 results)?
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Mishra A, et al. Among authors: byrne mt. J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11. J Clin Oncol. 2022. PMID: 35816664
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ, Sanz G, Griffiths EA, Yee K, Kantarjian H, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illés Á, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell CL, Hao Y, Keer HN, Azab M, Döhner H. Roboz GJ, et al. Among authors: byrne mt. Blood Adv. 2024 Apr 23;8(8):2020-2029. doi: 10.1182/bloodadvances.2023012062. Blood Adv. 2024. PMID: 38231126 Free PMC article. Clinical Trial.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Merryman RW, et al. Among authors: byrne mt. Blood Adv. 2021 Mar 23;5(6):1648-1659. doi: 10.1182/bloodadvances.2020003556. Blood Adv. 2021. PMID: 33710337 Free PMC article.
Distinguishing ASH Clinical Practice Guidelines from Other Forms of ASH Clinical Advice.
Cuker A, Kunkle R, Bercovitz RS, Byrne MT, Djulbegovic B, Haberichter SL, Holter-Chakrabarty J, Lottenberg R, Pai M, Rezende SM, Seftel MD, Silverstein RL, Terrell DR, Cheung MC. Cuker A, et al. Among authors: byrne mt. Blood Adv. 2024 Apr 9:bloodadvances.2023011102. doi: 10.1182/bloodadvances.2023011102. Online ahead of print. Blood Adv. 2024. PMID: 38593461
Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia.
Gatwood KS, Culos KA, Binari LA, Engelhardt BG, Kassim A, Byrne MT, Goodman SA, Chinratanalab W, Sengsayadeth SM, Greer JP, Jagasia M, Savani BN. Gatwood KS, et al. Among authors: byrne mt. Bone Marrow Transplant. 2018 Jun;53(6):795-799. doi: 10.1038/s41409-018-0124-6. Epub 2018 Mar 14. Bone Marrow Transplant. 2018. PMID: 29540851 No abstract available.
12 results